Takeda Ventures focuses on high-caliber therapeutic and platform based opportunities around the world.
Business Model:
Revenue: $30.4B
Employees: 10,001-999,999
Address: 1-1, Nihonbashi-Honcho 2-chome
City: Tokyo
State: tōkyō prefecture
Zip: 103-8668
Country: JP
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. We are based alongside Takeda’s R&a;D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda&s;s considerable R&a;D resources. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2015 | Encycle Therapeutics | Venture Round | 0 |
2/2018 | Wave Life Sciences | Post-IPO Equity | 60M |
12/2015 | Prosetta Biosciences | Series D | 31M |
2/2019 | BIOMx | Series B | 0 |
12/2017 | Obsidian Therapeutics | Series A | 0 |
8/2022 | Zelluna Immunotherapy | Venture Round | - |
11/2022 | Enzyre | Series A | 0 |
4/2022 | Be Biopharma | Series B | 0 |
3/2011 | CellCentric | Series B | - |
5/2017 | GammaDelta Therapeutics | Venture Round | 100M |
11/2018 | Axcelead | Seed Round | - |
5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
1/2006 | Symphogen | Series D | 0 |
1/2016 | Cortexyme | Series A | 15M |
4/2021 | Code Biotherapeutics | Seed Round | 0 |
5/2017 | BIOMx | Series A | 24M |
4/2020 | Cerevance | Series B | 65M |
9/2014 | BioMotiv | Venture Round | 25M |
2/2010 | Domainex | Venture Round | - |
4/2018 | Crescendo Biologics | Series B | 0 |
12/2016 | Hookipa Pharma | Series B | 10.7M |
11/2017 | Outpost Medicine, LLC | Series A | 20M |
1/2020 | Transine Therapeutics | Seed Round | - |
2/2021 | Xilio Therapeutics | Series C | 95M |
10/2020 | Be Biopharma | Series A | 52M |
6/2018 | StrideBio | Series A | 15.7M |
6/2007 | Serenex | Series D | 0 |
1/2020 | Emendo Biotherapeutics | Series B | 61M |
5/2020 | Amwell | Series C | 0 |
11/2019 | Protekt Therapeutics | Venture Round | 4.1M |
12/2013 | VHSquared | Series A | - |
5/2017 | OrphoMed | Series A | 39M |
10/2017 | Portal Instruments | Venture Round | 6M |
7/2012 | Juventas Therapeutics | Series B | 0 |
2/2019 | Hookipa Pharma | Series D | 37.4M |
2/2022 | Koneksa Health | Series C | 0 |
12/2014 | Naurex | Series C | 0 |
10/2005 | Serenex | Series C | 30M |
3/2021 | Presage Biosciences | Convertible Note | 6M |
11/2022 | hC Bioscience | Series A | 0 |
5/2021 | BridGene Biosciences | Series A | 0 |
10/2018 | Bsense Bio Therapeutics | Seed Round | 405k |
1/2020 | EvolveImmune Therapeutics | Venture Round | 17.5M |
8/2020 | ImmPACT Bio | Series A | 0 |
9/2018 | Ramino Bio | Seed Round | - |
4/2021 | Adaptate Biotherapeutics | Series A | 18.2M |
10/2019 | Arcellx | Series B | 0 |
2/2021 | Ensoma | Series A | 0 |
9/2020 | Palleon Pharmaceuticals | Series B | 100M |
2/2023 | Cerevance | Series B | 0 |
11/2013 | Hookipa Pharma | Series B | 27M |
6/2022 | Code Biotherapeutics | Series A | 0 |
6/2016 | Ultragenyx Pharmaceutical | Post-IPO Equity | 65M |
10/2018 | VelosBio | Series A | 58M |
8/2018 | Ambys Medicines | Series A | 60M |
11/2012 | ArmaGen Technologies | Series A | 0 |
3/2021 | StrideBio | Series B | 0 |
5/2018 | Cortexyme | Series B | 76M |
3/2020 | Redpin Therapeutics | Series A | 15.5M |
6/2011 | Redwood Bioscience | Venture Round | - |
12/2017 | Hookipa Pharma | Series C | 0 |
8/2016 | Bioniz Therapeutics | Series A | 0 |
5/2011 | Naurex | Series A | 18M |
6/2013 | Heptares Therapeutics | Series B | 0 |
10/2017 | Palleon Pharmaceuticals | Series A | 47.6M |
4/2005 | Receptor Biologix | Series A | 33.6M |
11/2020 | Catamaran Bio | Series A | 0 |
7/2018 | Presage Biosciences | Series D | 6M |
5/2023 | OncoResponse | Venture Round | 0 |
1/2023 | Ensoma | Series B | 0 |
5/2023 | Larkspur Biosciences | Series A | 0 |
10/2009 | Envoy Therapeutics | Series A | 8M |
8/2015 | Presage Biosciences | Venture Round | - |
4/2017 | Cortexyme | Debt Financing | 8M |
7/2018 | ARTham Therapeutics | Series A | - |
1/2018 | SEEDSUPPLY | Seed Round | - |
2/2006 | Lectus Therapeutics | Series A | 14.3M |
2/2022 | hC Bioscience | Series A | 0 |
10/2021 | Egle Therapeutics | Series A | 0 |
6/2021 | Transine Therapeutics | Seed Round | 0 |
10/2007 | CellCentric | Venture Round | 4.3M |
12/2021 | Integra Therapeutics | Seed Round | 0 |
7/2004 | Serenex | Venture Round | 8M |
3/2020 | Xilio Therapeutics | Series B | 100.5M |
7/2021 | Turnstone Biologics | Series D | 0 |
7/2020 | VelosBio | Series B | 137M |
6/2021 | Ribon Therapeutics | Series C | 0 |
11/2019 | Avidity Biosciences | Series C | 0 |
1/2019 | Ribon Therapeutics | Series B | 65M |
1/2021 | Aspen RxHealth | Series B | 23M |
5/2023 | Larkspur Biosciences | Series A | 0 |
5/2023 | OncoResponse | Venture Round | 0 |
2/2023 | Cerevance | Series B | 0 |
1/2023 | Ensoma | Series B | 0 |
11/2022 | hC Bioscience | Series A | 0 |
11/2022 | Enzyre | Series A | 0 |
8/2022 | Zelluna Immunotherapy | Venture Round | - |
6/2022 | Code Biotherapeutics | Series A | 0 |
4/2022 | Be Biopharma | Series B | 0 |
2/2022 | hC Bioscience | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|